Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01343667 · ClinicalTrials.gov registry record · NA
GORE Flow Reversal System and GORE Embolic Filter Extension Study
A NA study, sponsored by W.L.Gore & Associates.
- Completed
- Registry status
- NA
- Development phase
- 1,397
- Enrollment target
NCT01343667: Completed NA study, sponsored by W.L.Gore & Associates.
NCT01343667 is a NA study that has completed, run by W.L.Gore & Associates. The registered enrollment target is 1,397 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01343667, a NA study, has completed, sponsored by W.L.Gore & Associates.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,397 participants
- Enrollment target
Study Summary
The objective of this study is to provide an ongoing evaluation of clinical outcomes associated with the GORE Flow Reversal System and the GORE Embolic Filter when used for embolic protection during carotid artery stenting.
Primary Outcome
Major Adverse Events include death, stroke and myocardial infarction
Interventions
- DEVICE Gore Flow Reversal System
- DEVICE Gore Embolic Filter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,397 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-01 |
| Phase | NA |
What the finished NCT01343667 record still lists
NCT01343667 is an interventional study that assigns participants to a tested intervention. Its 1,397 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Gore Flow Reversal System is the first listed.
NCT01343667 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01343667 about?
NCT01343667 is a clinical study titled "GORE Flow Reversal System and GORE Embolic Filter Extension Study". The objective of this study is to provide an ongoing evaluation of clinical outcomes associated with the GORE Flow Reversal System and the GORE Embolic Filter when used for embolic protection during carotid artery stenting.
What is the current status of trial NCT01343667?
This trial is currently completed. It is a NA study. The enrollment target is 1,397 participants. The study started on 2011-04. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01343667?
The interventions under investigation include: Gore Flow Reversal System (DEVICE), Gore Embolic Filter (DEVICE).
Who is sponsoring clinical trial NCT01343667?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01343667's enrollment target sits among peer trials
1,397 73rd of 2000 higher than 1,928 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05006131 · 1,395 participants
Pancreatic Cancer Screening for At-risk Individuals
- NCT02205762 · 1,400 participants · Phase 2
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
- NCT02445222 · 1,400 participants · Phase 3
CAR-T Long Term Follow Up (LTFU) Study
- NCT03145077 · 1,400 participants · NA
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia